196 related articles for article (PubMed ID: 33470769)
41. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
42. Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback.
Kling JM; Dowling NM; Bimonte-Nelson HA; Gleason CE; Kantarci K; Manson JE; Taylor HS; Brinton EA; Lobo RA; Cedars MI; Pal L; Neal-Perry G; Naftolin F; Harman SM; Miller VM
Am J Physiol Regul Integr Comp Physiol; 2019 Dec; 317(6):R912-R920. PubMed ID: 31663769
[TBL] [Abstract][Full Text] [Related]
43. Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD.
Silverman DH; Geist CL; Kenna HA; Williams K; Wroolie T; Powers B; Brooks J; Rasgon NL
Psychoneuroendocrinology; 2011 May; 36(4):502-13. PubMed ID: 20810219
[TBL] [Abstract][Full Text] [Related]
44. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens.
Smith NL; Blondon M; Wiggins KL; Harrington LB; van Hylckama Vlieg A; Floyd JS; Hwang M; Bis JC; McKnight B; Rice KM; Lumley T; Rosendaal FR; Heckbert SR; Psaty BM
JAMA Intern Med; 2014 Jan; 174(1):25-31. PubMed ID: 24081194
[TBL] [Abstract][Full Text] [Related]
45. Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
Oh H; Madison C; Baker S; Rabinovici G; Jagust W
Brain; 2016 Aug; 139(Pt 8):2275-89. PubMed ID: 27190008
[TBL] [Abstract][Full Text] [Related]
46. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
Mijatovic V; van der Mooren MJ; Kenemans P; de Valk-de Roo GW; Netelenbos C
Menopause; 1999; 6(2):134-7. PubMed ID: 10374220
[TBL] [Abstract][Full Text] [Related]
47. Effect of menopausal hormone therapy on proteins associated with senescence and inflammation.
Faubion L; White TA; Peterson BJ; Geske JR; LeBrasseur NK; Schafer MJ; Mielke MM; Miller VM
Physiol Rep; 2020 Aug; 8(16):e14535. PubMed ID: 32857481
[TBL] [Abstract][Full Text] [Related]
48. Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis.
Henderson VW; St John JA; Hodis HN; McCleary CA; Stanczyk FZ; Shoupe D; Kono N; Dustin L; Allayee H; Mack WJ
Neurology; 2016 Aug; 87(7):699-708. PubMed ID: 27421538
[TBL] [Abstract][Full Text] [Related]
49. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women.
Sumino H; Ichikawa S; Kasama S; Takahashi T; Kumakura H; Takayama Y; Kanda T; Kurabayashi M
Atherosclerosis; 2006 Dec; 189(2):436-42. PubMed ID: 16469323
[TBL] [Abstract][Full Text] [Related]
50. Do different delivery systems of hormone therapy have different effects on psychological symptoms in surgically menopausal women? A randomized controlled trial.
Baksu B; Baksu A; Göker N; Citak S
Maturitas; 2009 Feb; 62(2):140-5. PubMed ID: 19179026
[TBL] [Abstract][Full Text] [Related]
51. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study.
Hemelaar M; van der Mooren MJ; Mijatovic V; Bouman AA; Schijf CP; Kroeks MV; Franke HR; Kenemans P
Menopause; 2003; 10(6):550-8. PubMed ID: 14627865
[TBL] [Abstract][Full Text] [Related]
52. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women.
Ho JY; Chen MJ; Sheu WH; Yi YC; Tsai AC; Guu HF; Ho ES
Hum Reprod; 2006 Oct; 21(10):2715-20. PubMed ID: 16807281
[TBL] [Abstract][Full Text] [Related]
53. Associations between pituitary-ovarian hormones and cognition in recently menopausal women independent of type of hormone therapy.
Kling JM; Dowling NM; Bimonte-Nelson H; Gleason CE; Kantarci K; Stonnington CM; Harman SM; Naftolin F; Pal L; Cedars M; Manson JE; James TT; Brinton EA; Miller VM
Maturitas; 2023 Jan; 167():113-122. PubMed ID: 36395695
[TBL] [Abstract][Full Text] [Related]
54. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group.
Good WR; John VA; Ramirez M; Higgins JE
Climacteric; 1999 Mar; 2(1):29-36. PubMed ID: 11915854
[TBL] [Abstract][Full Text] [Related]
56. Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals.
Perrotin A; Mormino EC; Madison CM; Hayenga AO; Jagust WJ
Arch Neurol; 2012 Feb; 69(2):223-9. PubMed ID: 22332189
[TBL] [Abstract][Full Text] [Related]
57. 17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis.
Rioux JE; Devlin MC; Gelfand MM; Steinberg WM; Hepburn DS
Menopause; 2018 Nov; 25(11):1208-1213. PubMed ID: 30358715
[TBL] [Abstract][Full Text] [Related]
58. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
[TBL] [Abstract][Full Text] [Related]
59. Bioidentical hormones for women with vasomotor symptoms.
Gaudard AM; Silva de Souza S; Puga ME; Marjoribanks J; da Silva EM; Torloni MR
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010407. PubMed ID: 27479272
[TBL] [Abstract][Full Text] [Related]
60. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
